Kerna VenturesPioneers of Promise: Top 40 in Gene DeliveryEven as numerous gene therapies clear regulatory hurdles, one obstacle continues to cast a shadow over progress: delivery.May 1May 1
Kerna VenturesGene Editing — Now FDA-blessed.In December 2023, the CRISPR/Cas9 gene editing therapy, known as exa-cel, received FDA approval.Dec 17, 2023Dec 17, 2023
Kerna VenturesGenerative AI: Hype & BeyondOur aim this time was to look at the underside of the generative AI iceberg..May 30, 2023May 30, 2023
Kerna VenturesTrillions Within Us: The Microbiome First UnicornsAs humans, we often think of ourselves as solitary entities, with our thoughts and actions driven solely by our own decisions...Apr 13, 2023Apr 13, 2023
Kerna VenturesFrom Kernel to RNA: the Story Behind Kerna VenturesAt Kerna Ventures, we are driven by a passion for innovation in physics, biology, and computer science...Apr 12, 2023Apr 12, 2023
